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Effect of chronic treatment with the gonadotrophin-releasing
hormone agonist azagly-nafarelin on basal concentrations
of LH in prepubertal bulls
H. Jime´nez-Severiano1,2∗, M. J. D’Occhio3†, D. D. Lunstra4, M. L. Mussard1,2,
J. W. Koch1‡, L. R. Ehnis1§, W. J. Enright5 and J. E. Kinder1,2,¶
1Department of Animal Science, University of Nebraska, Lincoln, NE 68583-0908, USA;
2Department of Animal Sciences, The Ohio State University, 2029 Fyffe Road, Columbus,
OH 43210-1095, USA; 3Animal Sciences and Production Group, Central Queensland University,
Rockhampton, Queensland, Australia 4701; 4The US Department of Agriculture, Agriculture Research
Service, Roman L. Hruska US Meat Animal Research Center, Clay Center, NE 68933-0166, USA; and
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Administration of GnRH agonist for an extended period in-
hibits pulsatile LH release but enhances testicular function
of bulls. The mechanism whereby long-term administration
of GnRH agonist enhances testosterone concentration in
the blood of bulls has not been determined. The aim
of this study was to determine whether chronic treat-
ment with the GnRH agonist, azagly-nafarelin, increases
blood concentrations of LH and FSH in prepubertal
bulls. Two different doses of the GnRH agonist were
administered via Alzet mini-osmotic pumps for 28 days.
Blood samples were collected at 20 min intervals for 24 h
at days 2, 13 and 25 of treatment. Agonist-treated groups
had reduced testosterone pulse frequency (P < 0.05) and
increased mean and basal concentrations of testosterone
(P < 0.05) comparedwith untreated control bulls. Basal LH
concentrations were higher in agonist-treated bulls during
all three periods (P < 0.05) and overall (1 ng ml−1 higher,
compared with control bulls; P < 0.001). Frequency of
LH pulses in the agonist-treated groups was reduced to less
than one pulse in 24 h. Agonist-treated bulls tended to have
(P < 0.10) or had (P < 0.05) a slight but significant increase
in blood FSH concentration. In conclusion, the higher
blood testosterone concentration in bulls after prolonged
treatment with GnRH agonist may result, at least in part,
from changes in the testes induced by enhanced basal
concentration of LH.
Introduction
Chronic treatment with GnRH or GnRH agonist induces
desensitization of the anterior pituitary gland (Labrie
et al., 1980; Bint Akhtar et al., 1983; Schu¨rmeyer et al.,
1984; Lincoln et al., 1986). In many species, including
rats (Labrie et al., 1980), rhesus monkeys (Bint Akhtar
et al., 1983; Sundaram et al., 1984), dogs (Vickery
et al., 1985), humans (Schu¨rmeyer et al., 1984) and
sheep (Fraser and Lincoln, 1980; Lincoln et al., 1986),
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pituitary desensitization is characterized by decreased
gonadotrophin secretion and reduced responsiveness to
further GnRH stimulation. Pituitary desensitization to
GnRH and the resulting decrease of LH concentration
in blood induces impairment of gonadal function, which
can eventually lead to azoospermia and infertility (Labrie
et al., 1980; Bint Akhtar et al., 1983; Vickery et al.,
1985). Cattle appear less sensitive to the negative effects
of chronic administration of GnRH (Melson et al., 1986;
Ronayne et al., 1993; D’Occhio and Aspden, 1996).
For example, chronic treatment with GnRH or GnRH
agonist in bulls is associated with enhanced testicular
function, as evidenced by increased concentrations of
testosterone in the blood (Melson et al., 1986; Ronayne
et al., 1993; D’Occhio and Aspden, 1996), greater testic-
ular size (D’Occhio and Aspden, 1996; Aspden et al.,
1998), increased numbers of testicular LH receptors
(Melson et al., 1986) and enhanced steroidogenic
and spermatogenic capacities (Aspden et al., 1998).
Paradoxically, increased steroidogenic capacity occurs
in bulls treated with agonist even though bulls have
c© 2003 Society for Reproduction and Fertility
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a classical downregulation of the pituitary gland.
Downregulation of the pituitary gland is associated with
a lack of responsiveness to exogenous GnRH stimulation
(Melson et al., 1986; D’Occhio and Aspden, 1996),
decreased numbers of GnRH receptors (Melson et al.,
1986), lower pituitary content of LH and FSH (Melson
et al., 1986; Aspden et al., 1996) and lower amounts
of LH- and FSH- subunit mRNA (Aspden et al., 1996,
1997). Similarly, female cattle treated with GnRH agonist
show enhanced luteal function (Davis et al., 2000) and
have increased blood concentrations of progesterone
(Gong et al., 1995; Davis et al., 2000) and oestradiol
(Bergfeld et al., 1996a).
The mechanism(s) whereby agonists induce functional
and morphological changes in the testes of bulls is not
known. It is possible that the apparent enhancement
of testicular function in bulls treated with GnRH
agonist may result from changes in LH status, including
alterations in basal secretion, characteristics of pulsatile
secretion or mean plasma concentrations. A lack of
pulsatile secretion of LH in cattle during agonist
treatment has been associated with normal (Melson et al.,
1986; Ronayne et al., 1993; Bergfeld et al., 1996a,b)
or slightly higher (Gong et al., 1995; D’Occhio and
Aspden, 1996) than normal mean plasma concentrations
of LH. The sampling frequencies in these studies
unfortunately did not allow a precise description of
individual components of the LH secretory profile.
Accordingly, the primary aim of the present study was
to provide a thorough description of the characteristics
of LH secretion in bulls treated with GnRH agonist.
This information is fundamental to understanding the
biological basis for increased steroidogenic function
in bulls treated with GnRH agonist that have a
downregulated pituitary gland. It is hypothesized that
chronic treatment with GnRH agonist in bulls results in
increased basal concentrations of LH in the blood and
that this provides the basis for increased testicular LH
receptors and greater steroidogenic function. Changes
in FSH secretion were also monitored in order to
obtain a complete understanding of the characteristics of
gonadotrophin secretion in male cattle during treatment
with GnRH agonist.
Materials and Methods
Experimental animals
All protocols and procedures used in this experiment
were approved by the Institutional Animal Care and
Use Committee at the University of Nebraska, Lincoln.
Eighteen bull calves (1/4 Hereford, 1/4 Angus, 1/4
Pinzgauer, 1/4 Red Poll) were used. At the begin-
ning of the experiment, bull calves averaged 152 ±
0.6 days of age, and 182 ± 3.1 kg body weight (BW).
The GnRH agonist used was azagly-nafarelin ([D-Nal(2)6,
aza-Gly10]GnRH; Intervet International BV, Boxmeer).
Treatments
Bulls were randomly allotted to three groups and
each group was assigned to one of three treatments
(n = 6 bulls per group) as follows: a placebo group
treated with the vehicle (control), or treated with a
relatively small (1g kg−1 BW day−1; A1) or a relatively
large (3g kg−1 BW day−1; A3) dose of azagly-nafarelin.
This GnRH agonist is considered to be 200 times more
potent than the native GnRH in rats. The large dose
of azagly-nafarelin was similar in potency to a similar
GnRH agonist used in previous studies with young
bulls (Ronayne et al., 1993). The vehicle used was 5%
(w/v) mannitol diluted in distilled water. Treatments were
administered subcutaneously via an Alzet mini-osmotic
pump (model 2ML4; Alza Corp., Palo Alto, CA) for
28 days. Pumps were inserted beneath the skin over-
lying the ribs, under local anaesthetic. Before inser-
tion, pumps were pre-incubated overnight in 0.15 mol
sodium chloride l−1 at 37◦C, to ensure an immediate
release of the hormone after insertion of the pumps.
Blood sampling
Blood samples were taken every 2 h from 2 to 20 h
after inserting the pumps. At the end of this period,
serial blood samples (5 ml) were collected every 20 min
for 24 h (day 2). Additional serial blood samplings were
made on days 13 and 25 of the treatment period. Animals
were fitted with indwelling jugular catheters® (Tygon
flexible plastic tubing, ID: 1.27 mm, OD: 2.29 mm;
Norton Performance Plastics, Akron, OH) one day before
the start of each collection period. Blood samples were
allowed to clot at room temperature and were then stored
at 4◦C. Blood was centrifuged within 36 h of collection at
1500 g for 20 min at 4◦C. Serum was then decanted into
polypropylene vials and stored at –20◦C until assayed for
LH, FSH and testosterone concentrations.
Hormone radioimmunoassays
Concentrations of LH were determined in all samples
by a double-antibody radioimmunoassay (Wolfe et al.,
1989). The limit of detection was 140 pg ml−1. The intra-
and inter-assay coefficients of variation (CV) were 4.8
and 6.6%, respectively. Concentrations of FSH were
determined in selected samples (every 2 h) from the serial
blood sampling periods and in all the other samples col-
lected during the experiment. Determinations were made
by a double-antibody radioimmunoassay (Wolfe et al.,
1989). The limit of detection was 154 pg ml−1. The intra-
and inter-assay CVs were 2.4 and 3%, respectively.
Concentrations of testosterone were determined in
every other serial sample that was collected, and
in all the other samples collected during the exper-
iment. Duplicate 25l aliquots of sample were
double-extracted with ether, and extract residues were
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re-suspended in 600l Tris-buffered saline with 0.1%
(w/v) gelatin (TBS-gel), to be assayed by a double-
antibody radioimmunoassay, using a micro-scale method
for liquid scintillation counting (Grotjan and Steinberg,
1978). The assay used a sheep anti-T antibody (GDN
no. 250; 200l of a 1:120 000 dilution), provided by
G. Niswender (Colorado State University, Fort Collins,
CO), [1,2,6,7-3H (N)] testosterone (24 000 d.p.m per
tube; New England Nuclear, Boston, MA); and donkey
anti-sheep gamma globulin (DSG 1002; 200l of
a 1:55 dilution; ImmunoVision, Springdale, AR) as
second antibody. The standard curve was prepared
with testosterone in solution with ethanol (3.6–461.4 pg
(25l)−1), allowed to dry and re-suspended in TBS gel.
The limit of detection was 50 pg ml−1. The intra- and
inter-assay CVs were 4.4 and 7.9%, respectively.
The validation of the radioimmunoassay for testoste-
rone was as follows. Fifteen different bull serum samples
were assayed at 10, 20 and 40l. These serial dilutions
generated binding inhibition curves that paralleled the
testosterone standard curve. Furthermore, the average
ratios ± SD and correlations of the testosterone concen-
trations obtained between the different pairs of volumes
were 0.94 ± 0.13 (r = 0.996), 0.99 ± 0.11 (r = 0.99)
and 0.93 ± 0.17 (r = 0.995) respectively, for 10 versus
20 l, 20 versus 40 l and 10 versus 40 l. Three bov-
ine serum samples were used to evaluate recovery of
mass. Different amounts of added testosterone were
utilized (50, 100, 200, 400 and 800 pmol per tube),
and the average ± SD recovery from these samples was
97 ± 3.9%.
Hormone secretory pattern and statistical analyses
Secretory patterns of LH and testosterone were
evaluated for mean and basal concentration and for
pulse frequency and amplitude, using computerized
algorithms (Merriam and Wachter, 1982; Pulsar software
modified for IBM-PC by J. F. Gitzen and V. D. Ramirez).
This method removes long-term trends, such as diurnal
rhythms, from the series of observations and calculates
a base line by generating a smoothed series that omits
peaks or trends with time constants less than 6 to 12 h.
It identifies peaks by criteria of both height and duration
of deviation from the base line, measured relative to the
expected random variability of the series. The smoothing
time was set to 12 h. The assay standard deviation used
in the algorithm was modelled as a quadratic function of
the dose for each hormone. G values used were: G(1) =
3.8, G(2) = 2.6, G(3) = 1.9, G(4) = 1.5 and G(5) = 1.2.
Data for LH and testosterone secretory patterns, and
mean concentrations of FSH on days 2, 13 and 25 of the
treatment were analysed as a completely randomized
design, using the MIXED procedure of SAS (Littell et al.,
1996) with the statement repeated, the options sub =
animal (treatment), and autoregressive (1) covariance
structure within animal. Treatment, day, and treatment-
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Fig. 1. Mean (± SE) serum concentrations of (a) LH, (b) testosterone
and (c) FSH in prepubertal bulls from 2 to 20 h after insertion of
the pumps. Bulls were treated with vehicle (control; ©), or with a
small (1 g kg−1 body weight (BW) day−1; A1: ), or large (3 g
kg−1 BW day−1; A3: ) dose of the GnRH agonist azagly-nafarelin
for 28 days.
by-day interaction were included in the model. The
PDIFF option of SAS was used to compare least square
means among treatments. Except for FSH concentration,
all variables were Log10 (Y+1) transformed so as to be
consistent with the assumptions of the ANOVA.
Results
Response to GnRH agonist during the initial
20 h of treatment
Hormonal concentrations in bulls from 2 to 20 h after
insertion of the mini-osmotic pumps are shown (Fig. 1).
Two hours after insertion of the pumps, concentrations
of LH (Fig. 1a) reached 84.49 ± 7.99 and 77.19 ±
15.23 ng ml−1, respectively, for groups A1 and A3, com-
pared with 2.33 ± 1.33 for the control group. Thereafter,
LH concentrations decreased in both groups to values
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Table 1. Average (± SEM) characteristics for LH secretory patterns in prepubertal bulls on days 2, 13 and 25 of treatment
Day of Mean Basal Pulse frequency Pulse amplitude
treatment Treatment* (ng ml−1) (ng ml−1) (pulses 24 h−1) (ng ml−1)
2 Control 1.67 ± 0.21e 0.99 ± 0.12b 3.00 ± 1.00a 10.11 ± 3.15
A1 2.36 ± 0.28d 2.35 ± 0.27a 0.00b –
A3 2.76 ± 0.32d 2.74 ± 0.32a 0.00b –
13 Control 1.60 ± 0.19 0.75 ± 0.07b 4.33 ± 0.84a 7.35 ± 1.36
A1 1.75 ± 0.08 1.70 ± 0.07a 0.17 ± 0.17b 3.16‡
A3 1.47 ± 0.09 1.44 ± 0.08a 0.17 ± 0.17b 0.84‡
25 Control 1.14 ± 0.24 0.62 ± 0.11e 1.83 ± 0.65d† 8.63 ± 0.85
A1 1.29 ± 0.06 1.28 ± 0.06d 0.00e –
A3 1.17 ± 0.16 1.10 ± 0.12d 0.67 ± 0.42de† 1.99 ± 1.17
Overall Control 1.47 ± 0.13 0.79 ± 0.07b 3.06 ± 0.52a 8.61 ± 1.16
A1 1.80 ± 0.14 1.78 ± 0.14a 0.06 ± 0.06b 3.16‡
A3 1.80 ± 0.20 1.76 ± 0.20a 0.28 ± 0.16b 1.61‡
*Bulls were treated with vehicle (control), or with a small (1g kg−1 body weight (BW) day−1; A1) or large (3g kg−1 BW day−1; A3)
dose of the GnRH agonist azagly-nafarelin for 28 days.
†Any two means with a dagger for the same variable and day tend to be different from each other (P < 0.10), but the effect is not
significant.
‡The standard error could not be calculated.
Means with different superscripts within variable and day are different: a,bP < 0.001; d,eP < 0.05.
comparable to control animals by 18 h (1.32 ±
0.25 ng ml−1). Testosterone concentrations (Fig. 1b)
followed a similar pattern to LH in both agonist-treated
groups, with values of 4.99 ± 0.76 ng ml−1 (A1) and
5.2 ± 1.1 ng ml−1 (A3) 2 h after insertion of the pumps,
decreasing to values similar to the control group
between 6 h (2.55 ± 0.37 ng ml−1 for group A1) and 12 h
(1.09 ± 0.42 ng ml−1 for group A3) after insertion of
the pumps. Concentrations of FSH (Fig. 1c) reached
3.69 ± 0.34 ng ml−1 by 2 h in group A1, and 3.77 ±
0.48 ng ml−1 by 4 h in group A3. Concentrations of FSH
then decreased to values similar to the control group
(1.58 ± 0.11 ng ml−1).
Characteristics of the LH secretory patterns on days 2,
13 and 25 of treatment
Characteristics of the LH patterns during the three 24 h
sampling periods are shown (Table 1). The interaction
of treatment by day was significant for mean LH
concentration (P < 0.05). Both agonist-treated groups
had higher (P < 0.05) mean concentrations of LH, com-
pared with the control group on day 2 only. The overall
effect of treatment on mean LH concentration was not
significant.
For basal concentration of LH, the effects of treatment
(P < 0.001) and treatment-by-day interaction (P < 0.05)
were significant. During the three periods of sampling,
both agonist-treated groups had higher (P < 0.05) basal
concentrations of LH compared with the control group.
The overall basal concentrations of LH in groups A1
and A3 were 1 ng ml−1 above the values detected in
the control group (P < 0.001).
The interaction of treatment by day was significant
(P < 0.05) for frequency of LH pulses. No LH pulses
were detected in almost all bulls treated with the GnRH
agonist during the three sampling periods. In group A1,
only one bull had one pulse during the sampling on
day 13. In group A3, one bull had two pulses on day
25, and another bull had one pulse on day 13 and two
pulses on day 25. During the three periods of sampling
and overall, pulse frequency was less (P < 0.001) in
both agonist-treated groups compared with the control
group.
Owing to the small number of pulses of LH in
the agonist-treated groups, on some days the standard
error for pulse amplitude could not be calculated and
it was not possible to make statistical comparisons
among treatments; therefore, only numerical data for
this variable are included (Table 1). Individual LH and
testosterone secretory patterns from one bull of each
group on day 13 of treatment are shown (Fig. 2). Basal
concentrations of LH and testosterone were higher in
both groups treated with the GnRH agonist (Fig. 2b,c)
compared with the control group. Patterns of LH and
testosterone secretory episodes also differed between
control and agonist-treated bulls. In control bulls
(Fig. 2a), LH pulses were characterized by a sharp in-
crease, followed by a gradual decrease until returning to
basal values; in addition, a pulse of testosterone usually
followed each pulse of LH. In contrast, the few pulses
of LH detected in bulls treated with the GnRH agonist
(Fig. 2c) were of small amplitude, had a longer period to
reach the peak and return to basal concentrations, and
were not clearly associated with subsequent increases of
testosterone.
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Characteristics of testosterone secretory patterns on
days 2, 13 and 25 of treatment
Treatment with both doses of GnRH agonist either
tended to increase (P < 0.10) or increased significantly
(P < 0.05) mean concentration of testosterone at each
day of sampling and overall (Table 2) compared with the
control group, except on day 13, when mean concen-
trations of testosterone were similar in group A3 and
the control group (P > 0.10). Bulls in group A1 tended
to have higher mean concentrations of testosterone
compared with those in group A3 on day 13 (P = 0.09),
although the effect was not significant, and had higher
mean testosterone concentrations on day 25 (P < 0.05).
Basal testosterone concentration was higher (P < 0.05)
in both agonist-treated groups compared with the control
group at each day of sampling. Furthermore, the overall
basal concentration of testosterone was higher (P < 0.05)
in groups A1 (12-fold) and A3 (8-fold) compared with the
control group. Bulls in group A1 tended to have higher
basal concentrations of testosterone compared with those
in group A3 on day 13 (P = 0.07) and had higher basal
concentrations on day 25 (P < 0.05).
Treatment with both doses of GnRH agonist reduced
(P < 0.05) the number of testosterone pulses in the
24 h sampling periods, except for group A3 at day 25.
Agonist-treated groups were different from each other in
number of testosterone pulses only on day 25 (P < 0.05).
Most testosterone pulses in the agonist-treated bulls
differed in shape compared with the bulls in the control
group, in a way similar to that described for LH pulses
(Fig. 2). A detectable pulse of LH did not always precede
pulses of testosterone in these groups. Considering the
apparent absence of LH pulses preceding testosterone,
it was unclear whether the increases in testosterone
were induced by release of LH, or were sustained
increases of testosterone responding to the constantly
higher basal concentrations of LH. Owing to the few
pulses of testosterone in the agonist-treated groups, on
some days the standard error for pulse amplitude could
not be calculated and it was not possible to make
statistical comparisons among treatments; therefore, only
numerical data for this variable are included (Table 2).
Concentrations of FSH on days 2, 13 and 25
of treatment
Data for mean concentration of FSH are shown
(Table 3). The effects of treatment and treatment-by-day
interaction were significant (P < 0.05). Bulls treated with
the small dose of GnRH agonist tended to have increased
(P = 0.08) FSH concentrations compared with the control
group on day 13, and had higher FSH concentrations on
days 2, 25 and overall (P < 0.05). Overall concentration
of FSH tended (P = 0.08) to be higher in group A3, and
was higher on days 2 and 25 (P < 0.05) compared with
the control group.
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Fig. 2. Individual secretory patterns of LH and testosterone in
prepubertal bulls on day 13 of treatment. Bulls were treated with
(a) vehicle (control), or with (b) a small (1g kg−1 body weight (BW)
day−1) or (c) a large (3g kg−1 BW day−1) dose of the GnRH agonist
azagly-nafarelin for 28 days. Samples were taken every 20 min
(LH) or every 40 min (testosterone) for 24 h, starting at 08:00 h.
Open circles denote LH concentration, small black circles denote
testosterone concentration and large black circles denote detected
LH pulses.
Discussion
The most significant finding in the present study was
a clear and consistent increase in basal concentration
of LH in bulls treated with the GnRH agonist, azagly-
nafarelin, regardless of the dose used. Although Ronayne
et al. (1993) reported a small increase in basal concen-
tration of LH in GnRH agonist-treated bulls, this increase
was observed only during the first day of treatment and
not on subsequent days. Furthermore, Melson et al.
(1986) suggested an increase in basal LH concentration
in bulls treated with nafarelin acetate, but this action
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Table 2. Average (± SEM) characteristics for testosterone secretory patterns in prepubertal bulls on days 2, 13 and 25 of treatment
Day of Mean Basal Pulse frequency Pulse amplitude
treatment Treatment* (ng ml−1) (ng ml−1) (pulses 24 h−1) (ng ml−1)
2 Control 0.79 ± 0.16e† 0.40 ± 0.07e 2.67 ± 0.88d 2.76 ± 0.64
A1 2.44 ± 0.82de† 2.45 ± 0.82d 0.17 ± 0.17e 1.18‡
A3 2.76 ± 0.83d 2.76 ± 0.84d 0.17 ± 0.17e 0.77‡
13 Control 1.64 ± 0.39e 0.47 ± 0.10e 3.67 ± 0.71d 4.89 ± 0.95
A1 6.35 ± 1.52d † 5.98 ± 1.45d† 1.00 ± 0.37e 4.08 ± 1.30
A3 3.88 ± 1.31de † 3.57 ± 1.18d† 1.00 ± 0.45e 2.56 ± 1.28
25 Control 1.35 ± 0.43e† 0.45 ± 0.07f 2.00 ± 0.68d 6.08 ± 1.67
A1 7.54 ± 1.04d 7.54 ± 1.03d 0.17 ± 0.17e 1.69‡
A3 3.76 ± 1.32e† 3.68 ± 1.34e 1.17 ± 0.31d 1.73 ± 0.47
Overall Control 1.26 ± 0.21e† 0.44 ± 0.04e 2.78 ± 0.45d 4.57 ± 0.69
A1 5.45 ± 0.82d 5.32 ± 0.80d 0.44 ± 0.17e 2.90 ± 0.10
A3 3.47 ± 0.65de† 3.34 ± 0.62d 0.78 ± 0.21e 0.93 ± 0.56
*Bulls were treated with vehicle (control), or with a small (1g kg−1 body weight (BW) per day; A1) or large (3g kg−1 BW per day;
A3) dose of the GnRH agonist azagly-nafarelin for 28 days.
†Any two means with a dagger for the same variable and day tend to be different from each other (P < 0.10), but the effect is not
significant.
‡The standard error could not be calculated.
Means with different superscripts within variable and day are different: d,e,fP < 0.05.
Table 3. Mean concentrations (± SEM) of FSH (ng ml−1) in prepubertal bulls on days 2, 13 and 25 of treatment
Day of treatment
Treatment* Day 2 Day 13 Day 25 Overall
Control 1.30 ± 0.05e 1.22 ± 0.11h 1.11 ± 0.11e 1.21 ± 0.05e†
A1 1.64 ± 0.08d 1.48 ± 0.14g 1.51 ± 0.12d 1.54 ± 0.07d
A3 1.67 ± 0.08d 1.21 ± 0.08h 1.39 ± 0.09d 1.42 ± 0.06de†
*Bulls were treated with vehicle (control), or with a small (1g kg−1 body weight (BW) day−1; A1) or large (3g kg−1
BW day−1; A3) dose of the GnRH agonist azagly-nafarelin for 28 days.
†Any two means with a dagger in the same day tend to be different from each other (P < 0.10), but the effect is not
significant.
Means with different superscripts within day are different or tend to be different: d,eP < 0.05; g,hP < 0.10.
of the GnRH agonist was not clearly shown. Therefore,
previous studies have shown inconsistent effects of the
GnRH agonists on LH concentration. The schedule of
sampling used in the present study (every 20 min for
24 h) allows for a more accurate characterization of the
LH secretory patterns, compared with single samples
per day or serial samplings made in shorter periods of
time, as used in previous studies. In the present study,
the increased basal concentration of LH in the agonist-
treated bulls was more marked at day 2 of treatment (137–
176% above the basal concentration in control bulls).
At days 13 and 25, basal LH in agonist-treated groups
was still 77–100% above the values detected in control
animals, indicating that increased basal concentrations
of LH in bulls chronically treated with the GnRH agonist
can be maintained over extended periods of time.
The reduced number or the lack of LH pulses in bulls
treated with GnRH agonists has been previously reported
(Melson et al., 1986; Ronayne et al., 1993; D’Occhio
and Aspden, 1996). Given that endogenous pulses of
GnRH are not suppressed by chronic treatment with the
GnRH agonist (Caraty et al., 1990), the suppression of LH
pulses indicates that the pituitary gland of cattle becomes
desensitized to endogenous GnRH pulses, similar to
the response in other species. Pituitary desensitization
is supported by findings in a related study in which
bulls treated with a GnRH agonist failed to respond to
exogenous administration of natural sequence GnRH, or
did not present the classical LH increase after castration
(D’Occhio and Aspden, 1996).
Another possibility is that the treatment with the GnRH
agonist changes the pulsatile pattern of LH, from a lesser
frequency and greater amplitude similar to that found
in the control bulls, to a greater frequency and lesser
amplitude pattern of LH secretion. If this had occurred,
pulses might not have been detected by the method used,
and basal LH would have been over-estimated. How-
ever, it is unlikely that this is the situation. The algorithm
used to analyse the LH episodes makes no assumptions
about ideal peak shapes. Instead, it requires that peaks
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have some combination of height and width. A peak is
detected if it is of great amplitude, even if it is narrow, or if
it has moderate amplitude, but extends for several points
in width (Merriam and Wachter, 1982). Furthermore, in
the authors’ experience, this method has been able to
detect LH pulses with amplitudes of 0.25 ng ml−1.
In the present study, and in previous studies (Melson
et al., 1986; Ronayne et al., 1993; Bergfeld et al.,
1996b; D’Occhio and Aspden, 1996), bulls chronically
treated with GnRH agonists have increased concen-
trations of testosterone in the blood. The reasons for
greater concentrations of testosterone when LH pulses
are essentially not occurring and when mean LH
concentration appears to be normal are unclear. Results
from the present experiment and data reported by others
(Chase et al., 1988; Mendis-Handagama et al., 1998)
support the hypothesis that the enhanced testicular
steroidogenesis and increased blood concentrations of
testosterone most likely result from the increased basal
concentration of LH in bulls chronically treated with
GnRH agonist. Previous studies in rams immunized
against GnRH and treated with LH for 12 to 20 days
indicate that the infusion of LH producing the highest
basal concentration of LH also resulted in the greatest
testosterone response to LH administration (Chase et al.,
1988). In adult rats, continuous infusion of LH for 2 weeks
induced hypertrophy and hyperplasia of Leydig cells, as-
sociated with a sixfold increase in testosterone secretory
capacity, with no change in testis volume (Mendis-
Handagama et al., 1998). Moreover, chronic treatment
of intact rats with LH or hCG results in increased
capacity for LH-stimulated testosterone production and
induction of steroidogenic enzyme synthesis (Payne
et al., 1980; O’Shaughnessy and Payne, 1982). Signs
of enhanced steroidogenesis are also reported for bulls
treated for 10 days with implants of the GnRH agonist
deslorelin (Aspden et al., 1998). The testes of these
bulls had increased amounts of StAR protein and the
steroidogenic enzymes P450scc and 3-hydroxysteroid
dehydrogenase, and 17-hydroxylase mRNA, indicating
increased testicular stimulation by LH, because the
synthesis of these enzymes is stimulated by LH (Saez,
1994).
In addition to the basal concentration of LH, greater
numbers of testicular receptors for LH might be important
for the increased synthesis of testosterone in bulls
treated with GnRH agonist, as shown by Melson et al.
(1986). Evidence that LH induces increased numbers and
activity of its own receptors has been shown by Kero
et al. (2000). This study used transgenic female mice
expressing a chimaeric protein derived from the subunit
of bovine LH and the carboxy-terminus peptide extension
of the hCG  subunit. The animals exhibited chron-
ically increased serum LH concentrations, associated
with increased numbers of adrenal LH receptors and
steroidogenic capacity.
In animals with increased basal LH concentration,
the testicular response observed corresponds to the
so-called long-term trophic effect of the hormone on
cellular structure and function, which requires mRNA
and protein synthesis (Saez, 1994). This long-term
response explains the changes in the Leydig cell pre-
viously reported, which might be important to maintain
increased testosterone synthesis for extended periods in
bulls chronically treated with GnRH or GnRH agonists.
The effect of GnRH agonists on FSH concentration
in bulls has not been well characterized. Aspden et al.
(1996) reported decreased serum FSH concentrations,
associated with decreased amounts of FSH- subunit
mRNA in the pituitary, in castrated bulls treated with
deslorelin. In contrast, Melson et al. (1986) reported no
effect of nafarelin acetate on serum FSH concentrations,
but noted a decreased pituitary content of FSH in mature
intact bulls. In the present study, there was a slight
increase in FSH concentrations in bulls treated with the
GnRH agonist. Whether this increase was biologically
important to the extent that it altered testicular function
(directly or indirectly on Leydig cells or any other
testicular component) is unknown. There is evidence in
immature hypophysectomized rats that treatment with
highly purified FSH can induce Leydig cell hypertrophy
and hyperplasia, associated with increased numbers of
LH receptors and steroidogenic capacity (Teerds et al.,
1989; Vihko et al., 1991).
In summary, the present study has shown that chronic
infusion with the GnRH agonist, azagly-nafarelin, in-
creases basal LH and induces a modest increase in
FSH mean concentration, associated with increased
concentration of testosterone in bulls. In addition, the
number and amplitude of LH pulses were reduced by
the treatment. In conclusion, these data support the
working hypothesis that the functional changes in the
testes of bulls chronically treated with GnRH agonists,
associated with enhanced steroidogenesis and testoster-
one secretion, most likely result from enhanced basal
secretion of LH. A possible effect of the small increase
of FSH concentration on testicular function cannot be
disregarded. The mechanisms inducing increased tonic
LH secretion by the downregulated pituitary remain to
be elucidated.
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